Spyre Therapeutics (SYRE) Interest & Investment Income (2015 - 2026)

Spyre Therapeutics (SYRE) has 12 years of Interest & Investment Income data on file, last reported at $7.0 million in Q1 2026.

• Quarterly Interest & Investment Income rose 7.73% year-over-year to $7.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.3 million (up 11.95% YoY) and the FY2025 annual result came in at $24.9 million, up 16.77% from the prior year.
• Interest & Investment Income slipped to $7.0 million in Q1 2026, from $7.1 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $7.1 million in Q4 2025 to a low of -$681000.0 in Q1 2024.
• A 5-year average of $2.5 million and a median of $420000.0 in 2023 frame the typical range for Interest & Investment Income.
• Annual changes were most pronounced in 2022 — Interest & Investment Income soared 1105.88% — and 2024, when it slumped 19300.0%.
• Tracing SYRE's Interest & Investment Income over 5 years: stood at $410000.0 in 2022, then surged by 906.34% to $4.1 million in 2023, then jumped by 39.99% to $5.8 million in 2024, then climbed by 23.6% to $7.1 million in 2025, then declined by 2.02% to $7.0 million in 2026.
• The last three Interest & Investment Income figures came in at $7.0 million (Q1 2026), $7.1 million (Q4 2025), and $5.4 million (Q3 2025), per Business Quant data.